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enucleation was employed had an operative blood loss
exceeding 1400mL. Depending upon intraoperative
hemodynamics, blood products were pro-bably trans-
fused in some patients. Albeit infrequent, transfusion
related risks can be life threatening. Ideally a surgical
technique for benign disease should eliminate any
transfusion risk when employed. Did the adjuncts used
herein .reduce blood loss? Unfortunately the data pres-
ented by Baer et al., leaves this question unanswered
because there are no data for comparison. Is the ration-
ale for arterial ligation sound? Substantiation that
preoperative angiography identified the exact arterial
supply to the hemangioma would support their con-
tention that extrahepatic ligation of the major hepatic
arterial branch to the hemangioma is advantageous.
However, that data was not presented. Moreover the
concept is suspect because the classic arterial supply to
hepatic hemangiomas is through multiple small pe-
ripheral arteries rather than a single dominant branch
arising extrahepatically from a main lobar hepatic
artery. If heman-giomas are enucleated, the arterial
supply will be ligated immediately adjacent to the
hemangioma anyway. Whether extrahepatic ligation
confers any additional benefit is unknown. Finally
Baer et al., favor intermittent vascular inflow occlusion
to the liver during enucleation. Unless the time for
enucleation of the hemangioma from the parenchyma
routinely exceeded 45-60 minutes, continuous rather
than intermittent occlusion would likely be more effec-
tive in reducing blood loss because intermittent perfu-
sion of the interface would be avoided.
Although the exact technique for resection of hema-
ngiomas may not need to be so elaborate, the concept
ofbroader application oflocal resection or enucleation
is laudable. Utilization ofthe plane ofcompressed liver
parenchyma adjacent to the hemangioma during con-
tinuous inflow vascular occlusion should allow enuc-
leation to be performed safely without sacrifice of
adjacent normal liver and without any permanent liver
ischemia. The technique of Baer et al., should be
heeded. Refinements will follow.
David M. Nagorney
Mayo Clinic
200 First Street SW, Rochester
MN 55905 U.S.A
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ABSTRACT
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Since previous reports have suggested that somatostatin may be of value in the control of
acute variceal haemorrhage, we compared its efficacy with that of injection sclerotherapy
in a randomised controlled clinical trial. Eighty consecutive patients with endoscopically-
proven severe variceai bleeding were randomised to injection sclerotherapy (n--41) or
somatostatin (n-- 39) given as a continuous infusion of 250 pg/h for 5 days plus daily
bolus administration of 250 pg. The efficacy of injection sclerotherapy and somatostatin
infusion in controlling haemorrhage and preventing rebleeding (censored at 5days),
mortality (censored at 28 days) and complications was compared. The aetiology of the
portal hypertension and transfusion requirementswas similar between the two groups, but
there were more patients with severe liver disease (Child’s C) in the somatostatin group.70 HPB INTERNATIONAL
There was no significant difference between the two treatments in the initial (p 1.0) or
overall control of bleeding (p--0.58). Furthermore, somatostatin was as effective as
injection sclerotherapy in cotrolling bleeding in patients with severe liver disease or in
those actively bleeding at the time of their endoscopy. The relative risk of rebleeding
whilst receiving somatostatin compared to injection sclerotherapy was 1.39 [95%
Confidence Interval (CI) 3.73; 0.52], but this was reduced to 0.98 (95% CI 0.37; 2.67)
when readjusted for Child’s grading, the only prognostic factor shown to be of signifi-
cance. Mortality was not significantly different between the two groups of patients
(p 0.31). The relative risk of dying whilst receiving somatostatin compared to injection
sclerotherapy was 1.6 (95% CI 3.93; 0.66) but was reduced to 1.03 (95% CI 0.47; 2.47)
when adjusted for Child’s grading, the only significant prognostic factor. Complications
in the somatostatin group were minor and less frequent than after injection sclerotherapy.
The results of this study indicate that somatostatin is a safe treatment, which is as
effective as endoscopic injection sclerotherapy for acute variceal bleeding.
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PAPER DISCUSSION
This paper is another in a series of clinical studies
attempting to determine the efficacy of intravenous
somatostatin for the treatment of bleeding esophageal
varices. Somatostatin is a 14 aminoacid peptide that
reduces splanchnic blood flow leading to a modest
reduction in hepatic blood flow and wedged hepatic
venous pressure,
2 with little effect on portal pressure
3
and intravariceal pressure4. Interest in this drug for
therapy of variceal hemorrhage developed because of
few side effects and comparable efficacy to vasopressin.
The costs of treatment however are significantly
greater.
This study is different because comparison is made
with endoscopic sclerotherapy, recognized to be effec-
tive treatment for control of acute variceal hemorr-
hage 5. In evaluating this study in the context of previ-
ously published reports, we need to examine the design
of the study. Patients with hemodynamically signifi-
cant variceal bleed were enrolled following an endos-
copy performed as "soon as possible" after admission.
Of the 111 patients referred for treatment, 80 patients
fulfilled their criteria and were randomized to either
therapy. Somatostatin was infused uninterrupted for
5 days at 250 ug/h after a bolus of 250 ug; the bolus was
repeated each day and when infusion was thought to be
interrupted while changing infusion bags. Balloon
tamponade was offered to patients if bleeding was
severe and was kept in place for 12 hours or until
definitive therapy was planned. Patients randomized
to endoscopic sclerotherapy received intravariceal in-
jections of2-3 ml of 5% ethanolamine oleate into each
variceal column and with the help of an overtube
advanced over a fiberoptic endoscope. Balloon tam-
ponade was placed for initial control of bleeding and if
oozing persisted after sclerotherapy. In both groups of
patients, the re-insertion of the balloon and continued
bleeding with or without hemodynamic instability
constituted treatment failure. At the end of 5days,
definitive therapy was commenced and efficacy of the
two treatments determined by assessment of 28 day
mortality and treatment related complications. Al-
though the frequency is not stated, the use of balloon
tamponade in this study to initially stabilize patients
and for rebleeding while on somatostatin infusion or
after sclerotherapy confirms the reliance of this group
on the beneficial effects of tamponade. Therefore, in
evaluating the efficacy of the two treatments under
study, we must interpret the results as showing the
combined effect of balloon tamponade with either of
these modalities.
The patient groups were well matched in terms of
age, gender, aetiology of liver disease, severity of liver
disease, index versus interval bleed, blood transfusion
requirement before and during the treatment and the
time that elapsed between referral, randomization and
inception of therapy. What is truly remarkable is that
the average time from onset of the bleed to hospital
admission was only 1.5 to 2 hours, and the average timeHPB INTERNATIONAL 71
from onset of bleed to start of treatment was 4 to
5 hours. These time related variables would be difficult
to reproduce in most centers and certainly attests to the
vigilance of this research team to respond to a variceal
bleeder with alarcity.
The results of this study however are interesting.
Endoscopic sclerotherapy controlled bleeding in
98%. Six of the 40 patients (15%) who rebled within
5 days were treated with balloon tamponade and
somatostatin; overall bleeding control was 83%. In
the somatostatin group, initial control of hemorrhage
was 97%, overall bleeding control was 77% and 8
patients (21%) rebled. Seven of these received balloon
tamponade, 3 ofwhom also received sclerotherapy and
all died following emergency esophageal transection.
Although rebleeding rates were similar in the two
groups, the choice of alternative treatment for either
group was different. For instance, patients in the
sclerotherapy group were offered balloon tamponade
and somatostatin rather than additional sclerotherapy
treatments or surgery. In the somatostatin group, all
patients received balloon tamponade, some received
sclero- therapy and eventually surgery was performed
in all. It is difficult therefore to assess the effect
of the two treatments on outcome when decisions
regarding alternative and definitive treatment were not
consistent.
While their results of endoscopic sclerotherapy
in initial control of hemorrhage, rebleeding and
mortality are similar to published reports,
6 it is not
clear why sclerotherapy failed in the somatostatin
patients who rebled. Sclerotherapy was effective in
only 1 of these 7 patients (15%), a significantly lower
rate than their initial sclerotherapy control rate of
98%. Why should prior infusion of somatostatin
contri-bute to decreased efficacy of sclerotherapy?
Did these patients have more severe liver disease or
become, decompensated with uncontrolled bleeding?
Such a possibility is plausible since all 7 patients
who received emergency esophageal transection died.
On the other hand the initial control of bleeding with
somatostatin is somewhat higher than seen in the large
clinical controlled studies where overall success of
64 to 68% were reported7-9. In these studies the ef-
ficacy of somatostatin was not consistently beneficial
since cessation of bleeding in controls occurred as
high as 830/08 What is puzzling is why any effect on
control of bleeding can be expected when this drug has
minimal effects on portal pressure and intravariceal
pressure.
The authors of this study conclude that somatos-
tatin should be offered to all patients as the initial
therapy for variceal bleeding since it’s efficacy equals
that of endoscopic sclerotherapy and because of it’s
easy administration. While there is merit in this recom-
mendation, one should question whether somatostatin
need be offered as an alternative to definitive therapy.
Should patients be continued on this drug for 5 days as
suggested in this study and by Burroughs et al.?9 Or
should somatostatin be used primarily to stabilize
patients initially while definitive therapy is being ar-
ranged or organized? Ultimately, treatment decisions
will be based on the time of patient presentation, con-
dition of the patient and the radiologic, surgical and
endoscopic expertise available at each center. For a
start anyway and for the initial management ofvariceal
hemorrhage, somatostatin seems good treatment.
References
1. Sonnenberg, G.E., Keller,.U. and Perruchud, A. et al. (1981)
Effect of somatostatin on splachnic hemo-dynamics in patients
with cirrhosis of the liver and in normal subjects. Gastroenterol-
ogy, $0, 526-532
2. Bosch, J., Kravetz, D. and Rodes, J. (1981) Effects ofsomatostatin
on hepatic and systemic hemodynamics in patients with cirrhosis
of the liver. Comparison with vasopressin. Gastroenterology, $0,
518-525
3. Sonnenberg, A. and West, C. (1983) Somatostatin reduces gastric
mucosal blood flow in normal subjects but not in patients with
cirrhosis of the liver. Gut, 24, 148-153
4. Kleber, G., Sauerbruch, T., Fischer, G. and Paumgartner, G.
(1988) Somatostatin does not reduce oesophgaeal variceal press-
ure in liver cirrhotics. Gut, 29, 153-156
5. Larson A. W., Cohen, H. and Zweiban, B. et al. (1989) Acute
esophageal variceal sclerotherapy. Results of a prospective ran-
domized controlled trial. JAMA, 255, 497-500
6. Terblanche, J., Burroughs, A. K. and Hobbs, K. E. F. (1989)Con-
troversies in the management of bleeding esophageal varices. N.
Eng. J. Med., 320, 1469-1475
7. Loperfido, S., Godena, F. and Tosolini, G. etal. (1987) La
somatatostatina nel tratamento dell’emorraga da varici
esofagogastriche. Recenti Prog. Med., 78, 82-86
8. Valenzuela, J.E., Schubert, T. and Fogel, M.R. et al. (1989)
A multicenter randomized double-blind trial of somatostatin in
the management of acute hemorrhage from esophageal varices.
Hepatology, 10, 958-961
9. Burroughs, A. K., McCormick, P. A. and Hughes, M. D. et al.
(1990) Randomized double-blind placebo controlled study of
somatostatin for control of variceal bleeding. Gastroenterology,
99, 1388-1395
Jacob Korula
Liver Unit
University of Southern California
Rancho Los Amigos Medical Center
Downey, California, USA